The acquisition by Merck KGaA is the primary catalyst; monitor for shareholder vote and regulatory approvals in Q1 2027. The Q3 results are largely backward-looking and overshadowed by the deal.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 12 $19.80entry
- T+1 · 4d ago +0.15%α +0.51% · $19.83
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Silence Therapeutics reported Q3 2026 net loss of $12.4 million ($0.08 per share), narrower than the $21.0 million loss ($0.15 per share) in Q3 2025, driven by lower R&D and G&A expenses. The filing is dominated by the pending acquisition by Merck KGaA, Darmstadt, Germany, announced on October 19, 2026, which is expected to close in Q1 2027.
Key Financial Metrics
Key Facts
- Net loss of $12.4 million for Q3 2026, compared to $21.0 million in Q3 2025
- Cash and cash equivalents were $247.7 million as of September 30, 2026, including $201.3 million from an upsized public offering in August 2026
- R&D expenses decreased to $9.3 million from $20.5 million year-over-year
- On October 19, 2026, Silence entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany
- Transaction expected to close in Q1 2027, subject to customary conditions
- Total outstanding shares were 186,609,073 as of September 30, 2026
Financial Impact
Net loss improved by $8.6 million year-over-year; cash position strengthened by $201.3 million from equity offering
Risk Factors
- Acquisition may not close due to regulatory or shareholder approval issues
- Competing acquisition proposals could emerge
- Litigation related to the transaction could cause delays or expenses
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-457060 |
| Document: d101909d8k.htm | 0001193125-26-457060 |
| Document: 0001193125-26-457060-index-headers.html | 0001193125-26-457060 |
| Document: 0001193125-26-457060-index.html | 0001193125-26-457060 |
| Document: 0001193125-26-457060.txt | 0001193125-26-457060 |
| 8-K Data (Synthetic) | 0001193125-26-457060 |
Track record
15 reports on SLN
4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +28.19% at T+60 after the Aug 10, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $19.72 Now $19.80 +0.42% settles Nov 24
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
- Nov 12, 20264d ago DEFA14A Neutral 4/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
- Nov 12, 20264d ago 8-K Neutral 5/10 Viewing Entry $19.80 Now $19.80 −0.00% settles Nov 19
- Nov 5, 202611d ago SC 13G Neutral 4/10 Entry $19.72 to $19.80 Now $19.80 +0.41% ▲ +0.41% −2.88% vs SPY
- Oct 19, 202628d ago DEFA14A Bullish 7/10 Entry $19.61 to $19.78 Now $19.80 +0.97% ▲ +0.87% +0.79% vs SPY
- Oct 19, 202628d ago DEFA14A Bullish 8/10 Entry $19.58 to $19.78 Now $19.80 +1.12% ▲ +1.02% +1.17% vs SPY
- Oct 19, 202628d ago 8-K Bullish 9/10 Entry $19.58 to $19.78 Now $19.80 +1.12% ▲ +1.02% +1.17% vs SPY
- Oct 13, 20264w ago SC 13G/A Neutral 3/10 Entry $8.98 to $19.67 Now $19.80 +120.49% ▲ +119.04% +118.59% vs SPY
- Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $8.98 to $19.67 Now $19.80 +120.49% ▲ +119.04% +118.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers